Free Newsletter
Obama's advisors identify vaccine fixes
No surprises here, but President Obama is being advised that quicker identification of pandemic viruses and a shift from egg-based to cell-culture production top the list of short-term measures to speed influenza vaccine production. The President's Council of Advisors on Science and Technology also named better seed strains, speedier methods of sterility testing, more reliable potency test reagents, and larger, updated fill/finish facilities.
The recommendations follow last year's delays in production of a pandemic vaccine. They were submitted by the council, for the most part, as short- and long-term measures. One item in a non-time-frame category: guidance from the FDA on what it takes to have a new flu vaccine approved.
Commissioner Margaret Hamburg can add that to her growing to-do list from her bosses. Near the top of that list are explanations to Congress regarding FDA actions surrounding Johnson & Johnson's Tylenol manufacturing violations, and for the unresolved elements of the heparin contamination of several years ago.
Longer-term recommendations of the President's council include study of obstacles and incentives for cell-culture production facilities; developing three recombinant flu vaccines; and development of a universal flu vaccine.
Another item on the long-term list: Implementing a new federal structure to oversee vaccine-production strategies. Let's hope this item gets bumped to the short-term list. As reported last week, the Department of Defense already has underway some of the initiatives (rapid viral vaccine production and a 12-week process for production of swine flu vaccine) recommended by the President's advisors.
- see this article
Related Articles:
Live From BIO: Vaccines in the 21st century
DoD funds Biovest, pushing vax-making tech
DoD examines 12-week flu vax process
Comments
Post new comment
Paid Research Reports
- Cloud Computing Adoption In The APAC Life Sciences Industry
- Pharmaceutical Licensing Overview
- Stakeholder Opinions: Vaccines in emerging markets (Latin America) - Opportunities in Brazil, Mexico and Argentina
- Pharmaceutical Key Trends 2010
- Commercial Insight: Top 20 Oncology Therapy Brands in Australia
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities


SHARE
WITH: